Opinion: Pelosi’s drug pricing plan puts medical innovation at risk
The Pelosi bill opens the door for bureaucrats in the U.S. and beyond to determine the type of research biopharma companies should pursue and how and when patients can access…
by Stephen J. Ubl
Oct 17, 2019
4 minutes
The future of medical innovation in America is at a crossroads.
Biopharmaceutical science is accelerating at a record pace, leading to new discoveries that are radically reshaping our ability to fight disease. At the same time, politicians in Washington, D.C., are considering legislation to lower drug costs this week that threatens this progress and would put us on a path to government-run health care.
As president and CEO of PhRMA, I recently got a chance to meet with scientists and tour the labs at several biopharmaceutical companies that are pioneering research in cell and gene therapies, two of the most promising areas of scientific
You’re reading a preview, subscribe to read more.
Start your free 30 days